CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
ConditionNon-Small Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Eligibility criteria
Qualifiers
Provide informed consent
18 years or older
Diagnosed with stage IV NSCLC
Currently receiving or previously received 1L EGFR-TKI treatment
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
590 Participants
are grouped into 2 trial groupsLocations
1Research Site610000, Chengdu China
Sponsors and collaborators
AstraZeneca
Lead sponsor
Source ClinicalTrials.gov